Amphastar Pharmaceuticals, Inc. Share Price
NASDAQ: AMPH | Small CapAmphastar Pharmaceuticals, Inc. Stock Performance
Open $21.73 | Prev. Close $21.87 | Circuit Range N/A |
Day Range $21.73 - $22.08 | Year Range $16.69 - $31.19 | Volume 10,053 |
Average Traded $21.96 |
Amphastar Pharmaceuticals, Inc. Share Price Today
As of 29 August 2026, Amphastar Pharmaceuticals, Inc.'s share price is $22.01. The stock opened at $21.73, compared to its previous close of $21.87. During today's trading session, Amphastar Pharmaceuticals, Inc.'s share price traded between $21.73 and $22.08, with an average price of $21.91. Over the past 52 weeks, the stock has recorded a high of $31.19 and a low of $16.69. In terms of performance, Amphastar Pharmaceuticals, Inc.'s share price has risen by 8.72% over the last six months and is down 28.11% on a year-on-year basis.
Amphastar Pharmaceuticals, Inc. Share Price Chart
Amphastar Pharmaceuticals, Inc. Stock Fundamentals & Key Indicators
Market Cap $1.03B | PE Ratio (TTM) 10.48 | Dividend Yield N/A |
EPS (TTM) $2.10 | Revenue (TTM) $719.89M | Return On Equity (TTM) 12.44% |
Profit Margin 13.63% | Debt to Equity 0.20 | Quarterly Earnings Growth YoY -57.09% |
Amphastar Pharmaceuticals, Inc. Quarterly Profit & Loss
All figures in USD
Amphastar Pharmaceuticals, Inc. Annual Profit & Loss
All figures in USD
About Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging, as well as Albuterol Sulfate inhalation aerosol. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Amphastar Pharmaceuticals, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $20.38 | $21.88 | +9.84% |
Jul 2026 | $20.35 | $19.92 | -1.09% |
Jun 2026 | $18.78 | $20.14 | +6.84% |
May 2026 | $21.93 | $18.85 | -14.12% |
Apr 2026 | $19.91 | $21.95 | +11.99% |
Mar 2026 | $20.45 | $19.60 | -3.19% |
Feb 2026 | $26.77 | $20.25 | -23.60% |
Jan 2026 | $26.90 | $26.50 | -1.05% |
Dec 2025 | $27.58 | $26.78 | -3.53% |
Nov 2025 | $24.98 | $27.76 | +8.73% |
Oct 2025 | $26.96 | $25.53 | -4.17% |
Sep 2025 | $30.82 | $26.64 | -12.98% |